Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like this is ready to move north.
Director bought 420,000 shares yesterday
http://www.sec.gov/Archives/edgar/data/1517022/000120919115035520/xslF345X03/doc4.xml
2014 Corporate Highlights
Announced positive top-line results from its Phase 2b study of AKB-6548 in non-dialysis patients with anemia related to CKD
Completed enrollment ahead of schedule in the original two cohorts of its Phase 2 study of AKB-6548 in patients with anemia related to CKD who are undergoing dialysis, and added an additional cohort designed to evaluate the safety, efficacy and tolerability of AKB-6548 dosed three times per week, administered in conjunction with a patient's hemodialysis schedule
Presented data from the AKB-6548 development program at the American Society of Nephrology 2014 Annual Meeting and the 2014 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 51st Congress
Strengthened corporate leadership with the addition of Brad Maroni, M.D. as Senior Vice President and Chief Medical Officer, Mark De Rosch, Ph.D. as Vice President of Regulatory Affairs and Tamara Dillon as Vice President of Human Resources
Added Ronald C. Renaud Jr., Michael Clayman, M.D., Maxine Gowen, Ph.D., and Michael Wyzga to the Board of Directors
Completed an initial public offering and fully exercised underwriters' option to purchase additional shares with net proceeds of the offering totaling $104.4 million
Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH
http://finance.yahoo.com/news/conatus-clinical-results-easl-meeting-110000672.html
well there comes the volume....In the wrong direction!
Nobody home today thus far. Where is the volume?
Hope so I loaded up here in the 2's
Same ole MOPEster can't hold it's gains. Went straight down from 2.48 pre-market.
This stock hit a low of $6.00 pre-market. I watched it move back up fast to $7.00. Got an order in for 6.80 which was filled and sold at $7.12 for a nice profit. I flipped this a few times during the day.
This stock is a perfect ATM for sure. It is rare that you are lucky enough to come across a mover like this. Just play the movement and you can make a fortune.
I was surprised it even got close to $8.00 plus again. I would not give up on this one.
@Investor666 · 19m 19 minutes ago
$BIOC-UDPDATE: Biocept Shares Rise 37% Following Report of Discussion of Liquid Biopsy at AACR 2015(Benzinga)
So what's driving this price action today other than most Biotechs having a green day. I don't see any news or PR's.
Was down pre-market as low as 1.22 but moved back up to 1.34 now.
Good luck. Heavy volume coming in now.
Sounds like you are in good shape to me. Should at least hit $2.00 soon with a PR here and there.
I wasn't willing to risk more than that. My gut told me not to. Turned out I was right. Maybe somewhere down the roads things will change. Sometimes in a heartbeat.
I hope you're going to flip the shares you bought at a lower price. Best way to get your average down. Don't get caught holding too much.
For the record I own a measly 350 shares. I figured if it tripled I was going to make out. On the other hand a 50% drop I could easy average down and get out at some point. Or hold for the hell of it. Whatever.
I better get out of here before I get into troulbe. Good luck!
Don't even get me started on ANALysts. They upgrade everything after the fact like after an FDA approval. They'll probably downgrade this in a week. Better job than being a weatherman, you can be wrong all the time and still get paid
Do you see this @ $9.00 today I don't. I think you are the one that missed something.
How many people do you think actually bought it @ .90 after watching it tank? Only the smart ones I suppose. You'll never see that agin until the next failure.I almost pulled the trigger. It will most likely be stuck here for awhile. What is the point of posting 24/7 it's not going to change anything.
Do you guys ever come up for air? 24/7 talking about a POS that failed miserably. This is never going anywhere. Give it a rest please.
Athersys stroke treatment fails study, shares slide
http://finance.yahoo.com/news/athersys-stroke-treatment-fails-study-103248286.html
Going backwards again. All that work to get to $3 with good news afterwards and yet here we are at 2.15.
Last Price
(0.01 NIS)
93.80 Change(%) + 8.06%
http://www.tase.co.il/Eng/General/Company/Pages/companyMainData.aspx?ShareID=01101518&CompanyID=001394&subDataType=0
(3) to approve an amendment to our Articles of Incorporation to increase the number of authorized shares of common stock, $.001 par value per share, from 100,000,000 shares to 250,000,000 shares;
http://ih.advfn.com/p.php?pid=nmona&article=66023978&symbol=SYN
This stock is toast for now. I wonder how low the manipulators will bring it.
Can MEI Pharma Survive?
http://247wallst.com/healthcare-business/2015/03/24/can-mei-pharma-survive/
This was kept down even as it was approaching the release of top-line data. The trading has always been very suspicious on this one.
$ATHX..."Athersys Inc.'s MultiStem could very well be among the first few products approved in Japan."
http://www.thelifesciencesreport.com/pub/na/will-stem-cell-profits-measure-up-nxr-biotechnologies-alain-vert-s
Yes I've been watching NVGN. It has had some very big spikes as of late. Up to about 4.50ish pre-market last week. I have yet to pull the trigger on buying it yet though. I'm looking at ATHX which has data coming up in April.
Yes I only held 100 shares which is nothing. I figured that was worth a gamble. I took some profits along the way.
MEI Pharma's cancer drug misses main goals in mid-stage study
http://finance.yahoo.com/news/mei-pharmas-cancer-drug-misses-112855550.html
I had a bad feeling about this one all along. I never liked the way it was trading. I held a very small amount through today. Play the bounce!
Do you plan on taking any profits? I would.
If you can't make money from 2.60ish last week to a high of 3.20 today then it's probably time to re-evaluate your trading techniques.
Athersys to Participate at 12th Annual BIO Asia International Conference
http://finance.yahoo.com/news/athersys-participate-12th-annual-bio-170000005.html
This "supposed" scam stock is doing really well now. Perhaps you should be making money off off it instead wasting energy on badmouthing it. The 1st rule of investing don't get emotional on what you own.
This stock is red hot as of late. I think it's going to pop big time soon.
$9.00 would be my guess. And then maybe it moves higher after the profit takers are gone.
Yes good ole Sheff. He alerted an insider buy of ANTH where I bought it at $1.45. Hit a high of 6.36 today. He follows me on Twitter. I'll make sure I get that buy info out there on Twitter ASAP like right now. He's like EF Hutton. Remember that commercial? When he talks or in this case posts people listen.
We still have no idea when this update exactly is do we? Mid March supposedly or it could be longer like ACHN did with their data.